Registered Kenya · PPB

WORMITREX

LEVAMIZOLE HYDROCHLORIDE

What it does

Levamisole is a medication used to treat infections caused by certain worms and to boost the immune system.

Commonly used for: worm infections (helminthiasis), immune system support

Read more in plain English ↓

Plain-language summary for general understanding - not medical advice. Always follow your pharmacist/doctor.

Ask about this medicine

Answers come only from this medicine's registration record, BNF monograph and interaction data - not medical advice.

Hard to find? We help patients in Kenya source rare medicines. We don't sell or dispense medicines - licensed pharmacies do.

Source this medicine

Registration & product details

Registration no.
56
Registration date
-
Expiry date
-
Status
Registered
Active ingredient
LEVAMIZOLE HYDROCHLORIDE
Dosage form
150MG/ML
Strength
-
Pack size
-
Therapeutic class
-
Manufacturer / MAH
Vetcare Kenya
Applicant / LTR
-
Country of origin
LOCAL
Manufacturer location
Nairobi, Kenya

Source: Pharmacy and Poisons Board · fetched 2026-01-28 21:26:07 · updated 2026-07-20 11:00:12

Disclaimer: This information is sourced from Pharmacy and Poisons Board (Kenya). Always consult a qualified healthcare professional before using any medication.

About this medicine

Levamisole is a medication used to treat infections caused by certain worms and to boost the immune system.

What it treats

  • worm infections (helminthiasis)
  • immune system support

How it works

Levamisole helps to kill worms in the body and also enhances the body's immune response.

Who it's for

It is used for people with specific worm infections and those needing immune system support.

AI-assisted summary grounded in BNF data - general information only, not medical advice. Always confirm with your pharmacist or doctor.

Clinical monograph: levamizole

Levamisole is an anthelmintic agent primarily used for the treatment of various parasitic worm infections, particularly in veterinary medicine and in certain human conditions. It is a synthetic derivative of imidazothiazole and works by disrupting the metabolism of helminths. Additionally, it has been used as an immune-modulating agent in certain diseases, including colorectal cancer and autoimmune disorders.

Indications

  • Ascariasis
  • Hookworm infection
  • Strongyloidiasis
  • Immunomodulation in colorectal cancer
  • Autoimmune diseases

Dosage

Children: Refer to the BNF for Children for specific paediatric dosing recommendations.

Adults: Refer to the BNF for specific adult dosing recommendations.

Mechanism of action

Levamisole acts by binding to nicotinic acetylcholine receptors on the muscle cells of helminths, leading to paralysis and expulsion of the parasites. It is also thought to enhance T-cell function and boost the immune system, particularly in the context of cancer therapy.

Pharmacodynamics

Levamisole exhibits its anthelmintic effects through neuromuscular paralysis of the parasites, which prevents them from attaching to the intestinal wall and allows for their elimination. Its immunomodulatory effects are attributed to its ability to enhance T-cell proliferation and stimulate interferon production, thus improving the host's immune response.

Pharmacokinetics

Levamisole is well absorbed after oral administration, with peak plasma concentrations occurring within 1 to 2 hours. It undergoes extensive hepatic metabolism, primarily through cytochrome P450 enzymes, and has a half-life of approximately 3 to 5 hours. The metabolites are primarily excreted via the urine. Food intake does not significantly affect its absorption.

Contra-indications

  • Hypersensitivity to levamisole or any of its components
  • Severe immunosuppression
  • History of agranulocytosis

Adverse effects

  • Nausea
  • Vomiting
  • Diarrhea
  • Abdominal pain
  • Rash
  • Agranulocytosis
  • Hepatotoxicity
  • CNS effects such as dizziness and headache

Interactions

  • Increased risk of agranulocytosis when used with other myelosuppressive agents
  • Possible interaction with warfarin, increasing anticoagulant effect
  • Caution with concurrent use of drugs that affect the liver

Precautions

  • Use with caution in patients with liver impairment
  • Monitor blood counts during therapy due to risk of agranulocytosis
  • Consider potential drug interactions before initiating therapy

Pregnancy

Levamisole is classified as category C. Use is not recommended unless the potential benefit outweighs the potential risk to the fetus.

Breast-feeding

It is not known whether levamisole is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Formulations

  • Tablets
  • Oral suspension

AI-synthesized from BNF references - general information only, not a substitute for professional medical advice or the current BNF. Verify doses with a pharmacist.